Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  capmatinib
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
C-met Inhibitor INCB028060 in Treating Patients with Papillary Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 09-25-0099, 140037, 340263, P131324, NCT02019693
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2109, NCI-2015-00412, NCT02159066
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CINC280X2102, NCI-2013-00488, 2010-024101-12, NCT01324479
C-Met Inhibitor INCB028060 and Erlotinib Hydrochloride in Treating Patients with Previously Treated Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#238, NCI-2013-01000, 435021, CINC280XUS02T, INC280, NCT01911507
Start Over